Literature DB >> 9771214

Low frequency of recent parvovirus infection in a population-based cohort of patients with early inflammatory polyarthritis.

B Harrison1, A Silman, E Barrett, D Symmons.   

Abstract

OBJECTIVE: To determine the contribution of human parvovirus B19 infection in explaining the incidence of early inflammatory polyarthritis (IP) in a population.
SETTING: The Norfolk Arthritis Register (NOAR) is a community-based programme aiming to ascertain all new cases of IP arising in a population that lead to attendance at primary care.
SUBJECTS: 147 newly ascertained subjects with IP with a disease duration of less than 16 weeks.
METHODS: Full clinical appraisal of all subjects who were followed up for three years. B19 IgM assayed with a third generation antibody capture enzyme immunoassay.
RESULTS: Only four (2.7%) patients had evidence of recent B19 infection, only one of whom did not satisfy criteria for rheumatoid arthritis (RA).
CONCLUSION: B19 infection does not explain more than a small proportion of either RA or undifferentiated IP cases occurring in the population.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9771214      PMCID: PMC1752621          DOI: 10.1136/ard.57.6.375

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  4 in total

Review 1.  Pathogenesis of human parvovirus B19 in rheumatic disease.

Authors:  J R Kerr
Journal:  Ann Rheum Dis       Date:  2000-09       Impact factor: 19.103

Review 2.  Should infection still be considered as the most likely triggering factor for rheumatoid arthritis?

Authors:  S M Carty; N Snowden; A J Silman
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

3.  Human parvovirus B19 viraemia is associated with neither IgM positivity nor anaemia in patients with rheumatic diseases.

Authors:  Y Munakata; T Saito
Journal:  Ann Rheum Dis       Date:  2006-02       Impact factor: 19.103

Review 4.  Human Parvoviruses.

Authors:  Jianming Qiu; Maria Söderlund-Venermo; Neal S Young
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.